Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPT90B
|
|||
| Drug Name |
Itepekimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J40-J44, J47; ICD-9: 490-492, 494-496] | Phase 3 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-33 (IL33) | Target Info | . | [2] |
| KEGG Pathway | Cytosolic DNA-sensing pathway | |||
| Influenza A | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04701983) Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health. | |||
| REF 2 | Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.